Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Endocrine Surgery

Cost Analysis of Radiofrequency Ablation (RFA) Compared With Thyroid Lobectomy

Monday, October 2, 2023
4:21 PM - 4:27 PM East Coast USA Time
Location: 201AB

    Presenting Author(s)

  • Jacqueline R. Tucker, MD

    Resident
    University of Minnesota
    Minneapolis, MN, United States

    • Co-Author(s)

  • QH

    Qiang Hao, n/a

    Penn State College of Health and Human Development, USA

  • Christopher S. Hollenbeak, PhD

    Professor
    The Pennsylvania State University
    University Park, PA, United States

  • Neerav Goyal, MD MPH FACS

    Associate Professor; Division Chief Head and Neck Surgery; Vice Chair Patient Safety and Quality
    Penn State Milton S. Hershey Medical Center
    Hershey, PA, United States

    • Senior Author(s)

  • David Goldenberg, MD

    Professor and Chair -Otolaryngology-Head and Neck Surgery
    Penn State University College of Medicine
    Hershey, PA, United States

Disclosure(s):
Neerav Goyal, MD MPH FACS: No relevant relationships to disclose.
Introduction: Radiofrequency ablation (RFA) is a minimally invasive treatment for benign thyroid nodules (BTN). However, the expected costs for RFA are unclear from a healthcare payer perspective as many payers have not defined reimbursement for RFA. Therefore, the objective of this study was to estimate one-year costs, including treatment and complication management, for RFA relative to thyroid lobectomy for patients with BTN and ultimately estimate a potential reimbursement threshold.

Methods: A decision tree model was created to model the natural history of BTN following treatment with RFA and lobectomy. Patients who underwent RFA were assumed to receive 1.2 treatment sessions on average. Probabilities of complications were obtained from the literature and electronic health record data. Costs were estimated from the healthcare payer perspective and derived from the Center for Medicare & Medicaid Services (CMS) fee schedule. Reimbursement of RFA for BTN is not yet defined. Therefore, we conservatively assumed a cost of $5,000 per session. Sensitivity analyses were performed to examine how sensitive the results were to changes in model parameters and to determine an equivalence threshold.

Results: The total one-year costs for RFA were $6,022, which was greater than the one-year costs of lobectomy, which were $4,492. However, in the sensitivity analysis, RFA became less costly when its cost fell 10.3% below the cost of lobectomy to $3,725. Complications included post-operative pain, hematoma, hypothyroidism, and hoarseness. RFA had lower rates of all complications compared to thyroid lobectomy. One-way sensitivity analyses suggested that these results were most sensitive to changes in costs of RFA and lobectomy and robust to the probabilities and costs of complications.

Conclusions: RFA has lower probabilities of all complications and lower expected one-year costs for complication management than lobectomy. A reimbursement threshold of $3,725 per session for RFA provides a similar one-year cost to lobectomy under the other assumptions in our model.